Open Access
Issue
Med Sci (Paris)
Volume 36, Number 11, Novembre 2020
Page(s) 1027 - 1033
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020174
Published online 05 November 2020
  1. Ilunga Kalenga O, Moeti M, Sparrow A, et al. The ongoing Ebola epidemic in the Democratic Republic of Congo, 2018–2019. N Engl J Med 2019; 381 : 373–83. [Google Scholar]
  2. Goldstein T, Anthony SJ, Gbakima A, et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol 2018 ; 3 : 1084–1089. [CrossRef] [PubMed] [Google Scholar]
  3. Reynard O, Volchkov V, Peyrefitte C. Une première épidémie de fièvre à virus Ebola en Afrique de l’Ouest. Med Sci (Paris) 2014 ; 30 : 671–673. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. https://www.who.int/publications/i/item/ebola-virus-disease-democratic-republic-of-congo-external-situation-report-85-2019. [Google Scholar]
  5. Editorial. DR Congo: managing Ebola virus in war. Lancet 2018; 392 : 1280. [Google Scholar]
  6. Wells CR, Pandey A, Parpia AS, et al. Ebola vaccination in the Democratic Republic of the Congo. Proc Natl Acad Sci USA 2019 ; 116 : 10178–10183. [CrossRef] [Google Scholar]
  7. Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004 ; 6 : 1–24. [Google Scholar]
  8. Reynard S, Journeaux A, Gloaguen E, et al. Immune parameters and outcomes during Ebola virus disease. JCI Insight 2019; 4. [Google Scholar]
  9. Diallo MSK, Rabilloud M, Ayouba A, et al. Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study. Lancet Infect Dis 2019 ; 19 : 308–316. [CrossRef] [PubMed] [Google Scholar]
  10. Ruibal P, Oestereich L, Lüdtke A, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature 2016 ; 533 : 100–104. [Google Scholar]
  11. Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013 ; 110 : 1893–1898. [CrossRef] [Google Scholar]
  12. Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011 ; 17 : 1128–1131. [CrossRef] [PubMed] [Google Scholar]
  13. Matz KM, Marzi A, Feldmann H. Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Rev Vaccines 2019 ; 18 : 1229–1242. [CrossRef] [PubMed] [Google Scholar]
  14. Lévy Y, Lane C, Piot P, et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet 2018 ; 392 : 787–790. [CrossRef] [PubMed] [Google Scholar]
  15. Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011 ; 85 : 4222–4233. [CrossRef] [PubMed] [Google Scholar]
  16. Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 2016 ; 315 : 1610–1623. [CrossRef] [PubMed] [Google Scholar]
  17. Mutua G, Anzala O, Luhn K, et al. Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. J Infect Dis 2019 ; 220 : 57–67. [CrossRef] [PubMed] [Google Scholar]
  18. Anywaine Z, Whitworth H, Kaleebu P, et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. J Infect Dis 2019 ; 220 : 46–56. [CrossRef] [PubMed] [Google Scholar]
  19. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011 ; 204 : (suppl 3) S1075–S1081. [CrossRef] [PubMed] [Google Scholar]
  20. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008 ; 4 : e1000225. [CrossRef] [PubMed] [Google Scholar]
  21. Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 2009 ; 83 : 7296–7304. [CrossRef] [PubMed] [Google Scholar]
  22. Huttner A, Dayer J-A, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 2015 ; 15 : 1156–1166. [CrossRef] [PubMed] [Google Scholar]
  23. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 2016 ; 374 : 1647–1660. [Google Scholar]
  24. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ça suffit !). Lancet 2017 ; 389 : 505–518. [CrossRef] [PubMed] [Google Scholar]
  25. Halperin SA, Arribas JR, Rupp R, et al. Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis 2017 ; 215 : 1789–1798. [CrossRef] [PubMed] [Google Scholar]
  26. Bache BE, Grobusch MP, Agnandji ST. Safety, immunogenicity and risk-benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in phase I-III clinical trials across regions. Future Microbiol 2020; 15 : 85–106. [CrossRef] [PubMed] [Google Scholar]
  27. Medaglini D, Harandi AM, Ottenhoff THM, et al. Ebola vaccine R&D: filling the knowledge gaps. Sci Transl Med 2015; 7 : 317ps24. [Google Scholar]
  28. Juan-Giner A, Tchaton M, Jemmy J-P, et al. Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea. Vaccine 2019 ; 37 : 7171–7177. [CrossRef] [PubMed] [Google Scholar]
  29. Davis C, Tipton T, Sabir S, et al. Post-exposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the UK: an operational, safety and immunogenicity report. Clin Infect Dis 2019; nov 30; ciz1165. doi: 10.1093/cid/ciz1165. [Google Scholar]
  30. Clarke DK, Xu R, Matassov D, et al. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis 2020; 20 : 455–66. [CrossRef] [PubMed] [Google Scholar]
  31. DiNapoli JM, Yang L, Samal SK, et al. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010 ; 29 : 17–25. [CrossRef] [PubMed] [Google Scholar]
  32. Blaney JE, Wirblich C, Papaneri AB, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol 2011 ; 85 : 10605–10616. [CrossRef] [PubMed] [Google Scholar]
  33. Bukreyev A, Marzi A, Feldmann F, et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009 ; 383 : 348–361. [CrossRef] [PubMed] [Google Scholar]
  34. Meyer M, Garron T, Lubaki NM, et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest 2015 ; 125 : 3241–3255. [CrossRef] [PubMed] [Google Scholar]
  35. Halfmann P, Ebihara H, Marzi A, et al. Replication-deficient ebolavirus as a vaccine candidate. J Virol 2009 ; 83 : 3810–3815. [CrossRef] [PubMed] [Google Scholar]
  36. Marzi A, Halfmann P, Hill-Batorski L, et al. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science 2015 ; 348 : 439–442. [Google Scholar]
  37. Dewitt T. Ebola vaccine inches toward human clinical trials. University of Wisconsin-Madison 2018. https://news.wisc.edu/ebola-vaccine-inches-toward-human-clinical-trials/. [Google Scholar]
  38. Kibuuka H, Berkowitz NM, Millard M, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 2015 ; 385 : 1545–1554. [CrossRef] [PubMed] [Google Scholar]
  39. Bengtsson KL, Song H, Stertman L, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine 2016 ; 34 : 1927–1935. [CrossRef] [PubMed] [Google Scholar]
  40. Fries L, Cho I, Krähling V, et al. A Randomized, blinded, dose-ranging trial of an Ebola virus glycoprotein (EBOV GP) nanoparticle vaccine with matrix-MTM adjuvant in healthy adults. J Infect Dis 2020; 222 : 572–82. [CrossRef] [PubMed] [Google Scholar]
  41. Marzi A, Hanley PW, Haddock E, et al. Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in Rhesus macaques infected with Ebola virus Makona. J Infect Dis 2016 ; 214 : S360–S366. [CrossRef] [PubMed] [Google Scholar]
  42. Falzarano D, Feldmann F, Grolla A, et al. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis 2011 ; 204 : suppl 3 S1082–S1089. [CrossRef] [PubMed] [Google Scholar]
  43. Natesan M, Jensen SM, Keasey SL, et al. Human survivors of disease outbreaks caused by Ebola or Marburg virus exhibit cross-reactive and long-lived antibody responses. Clin Vaccine Immunol 2016 ; 23 : 717–724. [Google Scholar]
  44. Legardy-Williams JK, Carter RJ, Goldstein ST, et al. Pregnancy outcomes among women receiving rVSVΔ-ZEBOV-GP Ebola vaccine during the Sierra Leone trial to introduce a vaccine against Ebola. Emerg Infect Dis 2020; 26 : 541–8. [CrossRef] [PubMed] [Google Scholar]
  45. Kennedy SB, Bolay F, Kieh M, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med 2017 ; 377 : 1438–1447. [Google Scholar]
  46. Mulangu S, Dodd LE, Davey RT, et al. A Randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019 ; 381 : 2293–2303. [Google Scholar]
  47. Kasereka MC, Ericson AD, Conroy AL, et al. Prior vaccination with recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection. Vaccine 2020; 38 : 3003–7. [CrossRef] [PubMed] [Google Scholar]
  48. WHO prime boost ebola report https://www.who.int/immunization/research/meetings_workshops/WHO_primeboost_Ebola_21nov14_meeting_report.pdf. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.